SNMMI Podcast Series

In this episode of the SNMMI Value Initiative Podcast, PharmaLogic’s Taylor Prejna speaks with Jessica Comstock, Vice President of Quality Assurance and Regulatory Affairs, about why quality and regulatory expertise is essential to successful radiopharmaceutical development. They explore the unique demands of the modality, from short product timelines and evolving regulations to isotope supply and global commercialization, and discuss how early collaboration with a CDMO’s quality and regulatory teams can reduce risk, support scalability, and ultimately improve patient access.

This podcast is sponsored by PharmaLogic, a Value Initiative member. 
Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X

Your TBR (AKA “to be read”) list may be pretty long if you’re a student, if you’re trying to keep up with the trends on Book Tok, or if you've just made a trip to your favorite local bookstore. Our two guests on this episode of the SNMMI podcasts also have extensive reading lists, but they’re not New York Times best sellers — they’re images of the human brain. Jake Dubroff and Derek Johnson both work in clinics that conduct amyloid and tau PET imaging at high volumes. The scans they’re reading give providers insight into what’s going on in the human brain, particularly when it comes to diagnosing Alzheimer’s and other neurodegenerative diseases.  But the use of the scans isn’t nearly as widespread as it could be, mainly due to implementation barriers. Even so, things seem to be changing, especially with the FDA's approval of FET that was only recently announced. To learn more about navigating the work that goes into reading scans, how clinics handle high volumes of patients, and the future role of nuclear medicine in brain imaging, tune into the discussion. Now streaming wherever you listen to podcasts!
This episode of the Podcast is sponsored by GE HealthCare.
Vizamyl Important Safety Information
PRODUCT INDICATIONS AND USE
VIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
Evaluation of Alzheimer's disease(AD) and other causes of cognitive decline
Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.
CONTRAINDICATIONS
VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.
ADVERSE REACTIONS
The most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%).
Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi 
Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X
Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X

Join moderator Lance Burrell and guests Mike Pintek, President, Nuclear & Precision Health Solutions (NPHS) and Dr. Ramji Rajendran, Radiation Oncologist, UroPartners, LLC, Medical Director of Theranostics and Radiation Oncologist with The Specialty Alliance as they speak about Alpha Therapy. 

This podcast is sponsored by Cardinal Health, a Value Initiative member. 
Disclaimer: The clinical views and opinions expressed in this presentation are those of the speakers and are based on their personal clinical experience. It should not be considered medical guidance. Any mention of a specific product is for illustration purposes.
Any verbal evaluations and opinions expressed by clinicians are independent and not approved by Cardinal Health.
This discussion addresses early-stage research, isotope supply, and operational considerations. Actinium-225-related applications discussed here are investigational unless and until specifically approved in product labeling. No statement should be interpreted as a recommendation regarding safety, effectiveness, patient selection, or standard-of-care use.
Health care providers are responsible for all medical decisions regarding the use of any drug products with their patients.
Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X

Join United Imaging, an SNMMI Value Initiative member, for an insightful discussion with moderator Lance Burrell and speakers Jennifer Robinson, Amanda Dieselkamp, and Will Cofer on the evolving role of mobile PET CT in expanding access to advanced molecular imaging. 

This podcast is brought to you by United Imaging, an SNMMI Value Initiative member. 

Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X

Was medical physicist an option at your school's career day? If so, lucky you! But if not, you're not alone. It's a pretty niche field, but it has a significant impact on the future of personalized medicine and treating diseases. If you're thinking that this sounds like an intriguing career path, we're joined by physicists working in several different areas of nuclear medicine: quality control, equipment calibration, and research. Ben Auer, PhD, hosts this episode as we learn more about how our guests discovered their career in medical physics, the qualifications needed, and the various opportunities that come with this highly rewarding field. Tune in now!
This episode of the Podcast is sponsored by GE HealthCare.
Vizamyl Important Safety Information
PRODUCT INDICATIONS AND USE
VIZAMYL™(flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
Evaluation of Alzheimer's disease(AD) and other causes of cognitive decline
Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.
CONTRAINDICATIONS
VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.
ADVERSE REACTIONS
The most commonly reported adverse reactions in clinical trials were flushing(2%), increased blood pressure(2%), headache nausea and dizziness(1%).
Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi 
Want more SNMMI content? Follow us on:
YouTube | Instagram | LinkedIn | Twitter/X